个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Ren Yonggang[1,2,3,*1] ; Yang Jing[1] ; Ding Zhiran[1] ; Zheng Menghua[1] ; Qiu Lu[4] ; Tang Aifa[5,*2] ; Huang Dandan[1] ;
机构： [1]Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China. [2]Research Center of Clinical Medical Sciences, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [4]School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China. [5]Shenzhen Luohu Hospital Group, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
出处：
DOI： 10.1111/cas.15887
ISSN：

关键词： cell proliferation ISGylation NFE2L3 p53 proteasome

摘要：
Nuclear factor erythroid 2-like 3 (NFE2L3) is a member of the cap 'n' collar basic-region leucine zipper (CNC-bZIP) transcription factor family that plays a vital role in modulating oxidation-reduction steady-state and proteolysis. Accumulating evidence suggests that NFE2L3 participates in cancer development; however, little is known about the mechanism by which NFE2L3 regulates hepatocellular carcinoma (HCC) cell growth. Here, we confirmed that NFE2L3 promotes HCC cell proliferation by acting as a transcription factor, which directly induces the expression of proteasome and interferon-stimulated gene 15 (ISG15) to enhance the proteasome-dependent degradation of ISGylated p53. Post-translational ISGylation abated the stability of p53 and facilitated HCC cell growth. In summary, we uncovered the pivotal role of NFE2L3 in promoting HCC cell proliferation during proteostasis. This finding may provide a new target for the clinical treatment of HCC.© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

基金：
Cooperation Project of Nanchong Science and Technology, Grant/Award Number: 22SXQT0221 and 20SXCXTD0004; National Natural Science Foundation of China, Grant/Award Number: 82172928; Natural Science Foundation of Sichuan Province, Grant/Award Number: 2022NSFSC0731; Research Development Fund of North Sichuan Medical College, Grant/Award Number: CBY19-YZ16 and CBY22-JQ01; Shenzhen Science and Technology Innovation Commission, Grant/Award Number:JSGG20191231141403880; Youth Scientific Research Project of Sichuan Medical Association, Grant/Award Number: Q21006
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China. [2]Research Center of Clinical Medical Sciences, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [*1]Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Gaoping District, Nanchong 637000, China
共同第一作者：
通讯作者：
通讯机构： [1]Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China. [2]Research Center of Clinical Medical Sciences, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [5]Shenzhen Luohu Hospital Group, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China. [*1]Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 55 Dongshun Road, Gaoping District, Nanchong 637000, China [*2]Shenzhen Luohu Hospital Group, The Third Affiliated Hospital of Shenzhen University, 47 Youyi Road, Luohu District, Shenzhen 518035, China
推荐引用方式(GB/T 7714)：
Ren Yonggang,Yang Jing,Ding Zhiran,et al.NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53[J].CANCER SCIENCE.2023,114(9):3523-3536.doi:10.1111/cas.15887.
APA：
Ren Yonggang,Yang Jing,Ding Zhiran,Zheng Menghua,Qiu Lu...&Huang Dandan.(2023).NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53.CANCER SCIENCE,114,(9)
MLA：
Ren Yonggang,et al."NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53".CANCER SCIENCE 114..9(2023):3523-3536

相关文献

[1]Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway [2]Aging-associated REGγ proteasome decline predisposes to tauopathy [3]食管鳞状细胞癌P53蛋白表达和基因突变与预后的关系 [4]p53、p16蛋白在52例食管鳞状细胞癌中的表达及其意义 [5]Deubiquitinating enzyme USP41 promotes lung cancer cell proliferation and migration. [6]TRPM2-AS promotes cancer cell proliferation through control of TAF15 [7]MiR-199a regulates cell proliferation and survival by targeting FZD7. [8]Association between SET expression and glioblastoma cell apoptosis and proliferation. [9]Overexpression of ATP5b promotes cell proliferation in asthma [10]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号